David Ian Wilson - 20 Jan 2026 Form 4 Insider Report for Neuphoria Therapeutics Inc. (NEUP)

Reporting relationship: Director
Issuer ticker: NEUP
Reported as of: 20 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 16:01:32 UTC
Prior SEC filing: 18 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Elaine Wangsawidjaja, Attorney-in-Fact for David Ian Wilson

Key filing fact

David Ian Wilson filed Form 4 for Neuphoria Therapeutics Inc. (NEUP) on 21 Jan 2026.

Key facts

This page summarizes David Ian Wilson's Form 4 filing for Neuphoria Therapeutics Inc. (NEUP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2026, 16:01.

Change

Previous filing in this sequence was filed on 18 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002028949 Primary reporting owner

Wilson David Ian

Relationship: Director
Address: 100 SUMMIT DRIVE, BURLINGTON
Signature: /s/ Elaine Wangsawidjaja, Attorney-in-Fact for David Ian Wilson
Signature date: 21 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NEUP transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +8,537
Change %: +124%
Price: $0.000000
Shares after: 15,412
Date: 20 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,537
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

Footnote F2

The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy.

Footnote F3

Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest.